RETRACTED ARTICLE: LRRK2 kinase regulates α-synuclein propagation via RAB35 phosphorylation

Bae, Eun-Jin, Kim, Dong-Kyu, Kim, Changyoun, Mante, Michael, Adame, Anthony, Rockenstein, Edward, Ulusoy, Ayse, Klinkenberg, Michael +8 more·2018·Nature Communications
DOI 10.1038/s41467-018-05958-z

Cited by (149)

Items 101–149 of 149

  1. Long-Term Exposure to PFE-360 in the AAV-α-Synuclein Rat Model: Findings and Implications
    Michael Aagaard Andersen, Florence Sotty, Poul Henning Jensen, Lassina Badolo, Ross Jeggo, Garrick Paul Smith, Kenneth Vielsted Christensen · 2019 · eNeuro
  2. Expression of G2019S LRRK2 in Rat Primary Astrocytes Mediates Neurotoxicity and Alters the Dopamine Synthesis Pathway in N27 Cells via Astrocytic Proinflammatory Cytokines and Neurotrophic Factors
    Dong Hwan Ho, Hye Jung Kim, Daleum Nam, Mi Kyoung Seo, Sung Woo Park, Ilhong Son · 2024 · Current Issues in Molecular Biology
  3. Invited review: Unearthing the mechanisms of age-related neurodegenerative disease using Caenorhabditis elegans
    Ashley N. Hayden, Emily J Leptich, Rachel N. Arey · 2022 · Comparative Biochemistry and Physiology Part A Molecular & Integrative Physiology
  4. Impairment of the Glial Phagolysosomal System Drives Prion-Like Propagation in a Drosophila Model of Huntington's Disease
    Graham H. Davis, Aprem Zaya, Margaret M.P. Pearce · 2024 · Journal of Neuroscience
  5. Retrogradely transmitted α-synuclein is taken up by the endophilin-independent endocytosis in the C. elegans neural circuit
    Xuan Wang, Yoichi Shinkai, Motomichi Doi · 2021 · Biochemical and Biophysical Research Communications
  6. Alpha‐Synuclein oligomerization and aggregation: All models are useful but only if we know what they model
    Hilal Ahmed Lashuel · 2020 · Journal of Neurochemistry
  7. Acrylamide induces the activation of BV2 microglial cells through TLR2/4-mediated LRRK2-NFATc2 signaling cascade
    Xiaoyu Yan, Qiuju Li, Shuangyue Wu, Liang Jie, Yuanyuan Li, Tingting Zhang, Dayi Chen, Xiaoqi Pan · 2023 · Food and Chemical Toxicology
  8. Genetic mutations in kinases: a comprehensive review on marketed inhibitors and unexplored targets in Parkinson's disease
    Amir Raza, Jeevika Raina, Sanjeev Kumar Sahu, Pankaj K. Wadhwa · 2025 · Neurological Sciences
  9. Therapeutic potential and limitation of condensed and hydrolyzed tannins in Parkinson's disease
    Runfan Zhao, Nan Jia, Shuyang Wu, Jiahui Wen, Yajun Huang, Chao Zhao, Weichao Chen · 2025 · International Journal of Biological Macromolecules
  10. An update on cellular and molecular determinants of Parkinson's disease with emphasis on the role of the retromer complex
    Vania Macías‐Calvio, Luz‐María Fuentealba, María‐Paz Marzolo · 2020 · Journal of Neuroscience Research
  11. Endogenous Rab29 does not impact basal or nigericin and monensin stimulated LRRK2 pathway activity
    Alexia F. Kalogeropulou, Jordana B. Freemantle, Paweł Lis, Edmundo G. Vides, Nicole K. Polinski, Dario R. Alessi · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  12. Unraveling Molecular Targets for Neurodegenerative Diseases Through Caenorhabditis elegans Models
    Rong-Mei Xu, Qiaoju Kang, Xuefei Yang, Ping Cheng Yi, Rongying Zhang · 2025 · International Journal of Molecular Sciences
  13. Genetic modifiers of synucleinopathies—lessons from experimental models
    Rachel Min Qi Lee, Tong‐Wey Koh · 2023 · Oxford Open Neuroscience
  14. Chaperones as Potential Pharmacological Targets for Treating Protein Aggregation Illness
    Shikha Rani, Minkal Tuteja · 2025 · Current Protein and Peptide Science
  15. LRRK2 and the fragile synapse: a molecular prelude to Parkinson’s disease?
    Beatrice Masotti, Giulia Tombesi, Loukia Parisiadou, Elisa Greggio · 2025 · Biochemical Journal
  16. New aspects of a small GTPase RAB35 in brain development and function
    Ikuko Maejima, Ken Sato · 2024 · Neural Regeneration Research
  17. Therapeutic Targeting of Autosomal Parkinson’s Disease by Modulation of Leucine-Rich Repeat Kinase 2 (LRRK2) Protein
    Zeeshan Hyderi, M Shirin Farhana, Tej Pal Singh, Arumugam Veera Ravi · 2025 · Brain Research
  18. Pathogenic LRRK2 requires secondary factors to induce cellular toxicity
    Evy Lobbestael, Chris Van den Haute, Francesca Macchi, Jean‐Marc Taymans, Veerle Baekelandt · 2020 · Bioscience Reports
  19. High Glucose Diet Attenuates Dopaminergic Neuronal Function in C. elegans Leading to Acceleration of Aging Process
    Arvie Camille V. de Guzman, Eun Ji Kim, Joong Hee Cho, Jin Ho Kim, Shin Sik Choi · 2020
  20. Low-usage splice junctions underpin immune-mediated disease risk
    Omar El Garwany, Nikolaos I. Panousis, Andrew J. Knights, Natsuhiko Kumasaka, Maria Imaz, Lorena Boquete Vilarino, A. Tsingene, Alice Barnett, Céline Gomez, Daniel J. Gaffney et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  21. Extracellular vesicle-mediated release of bis(monoacylglycerol)phosphate is regulated by LRRK2 and glucocerebrosidase activity
    Elsa Meneses‐Salas, Moises Castellá, Marianna Arnold, F. Hsieh, Rubén Fernández‐Santiago, Mario Ezquerra, Alícia Garrido, Marı́a José Martı́, Carlos Enrich, Suzanne R. Pfeffer et al. · 2025 · eLife
  22. The Dual Role of Glial Extracellular Vesicles in Neurodegeneration: Insights from iPSC-Based Models
    Aurora Scrivo, Liliana Inácio Bernardino, Antonella Consiglio · 2026 · International Journal of Molecular Sciences
  23. LRRK2 G2019S enhances immune response pathways and aggravates asthma in mouse models
    Kai Yang, Yaolong Zhou, Jie Cui, Wei‐Feng Tang, Yujun Chen, Xiqun Chen · 2024 · Biochemical and Biophysical Research Communications
  24. Therapeutic potential of leucine-rich repeat kinase 2 inhibitors for Parkinson's disease treatment
    Subhashree Sahoo, Amrita Arpita Padhy, Varsha Kumari, Kummari Shivani, Parul Mishra · 2022 · Elsevier eBooks
  25. The dynamic structure of Rab35 is stabilized in the presence of GTP under physiological conditions
    Takuya Murata, Yuka Unno, Mitsunori Fukuda, Naoko Utsunomiya‐Tate · 2020 · Biochemistry and Biophysics Reports
  26. Exacerbated Cellular Senescence in Human Dopaminergic Neurons along with an Increase in LRRK2 Kinase Activity
    Dong Hwan Ho, Minhyung Lee, Daleum Nam, Hye‐Jung Kim, Janghwan Kim, Mi Kyoung Seo, Sung Woo Park, Ilhong Son · 2025 · Biocell
  27. Modeling diseases of aging in larval zebrafish, a paradoxical yet powerful strategy
    Güliz Gürel Özcan, Jason Rihel · 2026 · Genetics
  28. Extracellular vesicle-mediated release of bis(monoacylglycerol)phosphate is regulated by LRRK2 and glucocerebrosidase activity
    Elsa Meneses‐Salas, Moisés Castellá, Marianna Arnold, F. Hsieh, Ruben Fernandez-Santiago, Mario Ezquerra, Alícia Garrido, Marı́a José Martı́, Carlos Enrich, Suzanne R. Pfeffer et al. · 2026 · eLife
  29. Parkinson’s disease and inflammatory bowel disease: exploring the connection between the two
    Xin Zhou, Xinyu Zhang, Huazheng Liang, Yong Bi · 2026 · Ageing and Neurodegenerative Diseases
  30. Leucine-Rich Repeat Kinase 2 Promotes Disintegration of Retinal Pigment Epithelial Cell
    Yuka Suimon, Moemi Nishimura, Miyuki Murata, Shiho Yoshida, Koichi Yokoi, Zhenyu Dong, Noriyuki Kuno, Shinobu Fujii, Zen‐ichi Tanei, Ichiro Yabe et al. · 2025 · American Journal Of Pathology
  31. Rab35 GTPase positively regulates endocytic recycling of cardiac KATP channels
    Bo Yang, Jia-Lu Yao, Jianyi Huo, Yu-Long Feng, William A. Coetzee, Guang‐Yin Xu, Hua-Qian Yang · 2022 · Channels
  32. Pathologic α-Synuclein Species Activate LRRK2 in Pro-Inflammatory Monocyte and Macrophage Responses
    Enquan Xu, Ravindra Boddu, Hisham Abdelmotilib, Kaela Kelly, Arpine Sokratian, Ashley S. Harms, Aubrey M Schonhoff, Nicole Bryant, Irene E. Harmsen, Michael G. Schlossmacher et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  33. Extracellular vesicle-mediated release of bis(monoacylglycerol)phosphate is regulated by LRRK2 and Glucocerebrosidase activity
    Elsa Meneses‐Salas, Marianna Arnold, Moises Castellá, F. Hsieh, Rubén Fernández‐Santiago, Mario Ezquerra, Alícia Garrido, Marı́a José Martı́, Carlos Enrich, Suzanne R. Pfeffer et al. · 2025 · eLife
  34. Advances in Disease Modifying Therapies for Parkinson's Disease
    Kambiz Hassanzadeh, M. Maral Mouradian · 2025 · Wiley eBooks
  35. Studying non–cell-autonomous neurodegeneration in Parkinson’s disease with induced pluripotent stem cells
    Tuuli-Maria Sonninen, L. M. Plotnikova, Nihay Laham-Karam, Gundars Goldsteins, Jari Koıstınaho, Šárka Lehtonen · 2021 · Elsevier eBooks
  36. Functional variant rs17525453 within RAB35 gene promoter is possibly associated with increased risk of Parkinson's disease in Taiwanese population.
    Hung‐Li Wang, Tu‐Hsueh Yeh, Ying‐Zu Huang, Yi-Hsin Weng, Rou‐Shayn Chen, Chin‐Song Lu, Kuo‐Chen Wei, Yu‐Chuan Liu, Ying-Ling Chen, Chao-Lang Chen et al. · 2021 · Neurobiology of Aging
  37. Inhibition of LRRK2 kinase activity promotes anterograde axonal transport and presynaptic targeting of α-synuclein
    Charlotte F. Brzozowski, Baraa A. Hijaz, Vijay Singh, Nolwazi Z. Gcwensa, Kaela Kelly, Edward S. Boyden, Andrew B. West, Deblina Sarkar, Laura A. Volpicelli‐Daley · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  38. Linking Genetic Risks to Pathological α-Synuclein Transmission in Parkinson’s Disease
    Xiaoqing Mi, Lei Chen, Junxia Xie, Ning Song · 2023 · Neuroscience Bulletin
  39. Sterol Biomarker Discovery In Neurodegenerative Diseases
    Manuela Pacciarini · 2023
  40. Parkinson’s Disease Associated with Mutations in the LRRK2 Gene: Approaches to Therapy
    Tatiana S. Usenko, S. N. Pchelina · 2025 · Molecular Biology
  41. Extracellular vesicle-mediated release of bis(monoacylglycerol)phosphate is regulated by LRRK2 and Glucocerebrosidase activity
    Elsa Meneses‐Salas, Moisés Castellá, Marianna Arnold, F. Hsieh, Rubén Fernández‐Santiago, Mario Ezquerra, Alícia Garrido, Marı́a José Martı́, Carlos Enrich, Suzanne R. Pfeffer et al. · 2025 · eLife
  42. Additional file 1 of Oligomerization of Lrrk controls actin severing and α-synuclein neurotoxicity in vivo
    Sarkar, Souvarish, Farah H. Bardai, Abby L. Olsen, Kelly M. Lohr, Zhang, Ying-Yi, Mel Β. Feany · 2021 · Figshare
  43. Additional file 1 of Pharmacological inhibition of nSMase2 reduces brain exosome release and α-synuclein pathology in a Parkinson’s disease model
    Chunni Zhu, Tina V. Bilousova, Samantha Focht, Michael Jun, Chris Jean Elias, Mikhail Melnik, Sujyoti Chandra, Jesus J. Campagna, Cohn, Whitaker, Asa Hatami et al. · 2021 · Figshare
  44. Additional file 1 of Small molecule inhibitors of α-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans
    Kevin S. Chen, Krystal S Menezes, Rodgers, Jarlath B., Darren M. O’Hara, Nhat Anh Tran, Kazuko Fujisawa, Seiya Ishikura, Khodaei, Shahin, Hien Chau, Anna Cranston et al. · 2021 · Figshare
  45. Etude de la coopération de l'alpha-synucléine et de LRRK2 dans les dysfonctions mitochondriales dans la Maladie de Parkinson
    Camille Gardier · 2019 · theses.fr (ABES)
  46. MicroRNA-181 influences Alzheimer’s risk by regulating neprilysin and microtubule-associated tau pathways, offering a novel target
    Ruizhi Wang, Bryan Maloney, Kwangsik T. Nho, John S. Beck, Scott Counts, Debomoy K. Lahiri · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  47. Nucleic acid therapeutics in neurodegenerative disorders: emerging technologies and clinical landscape
    Masahiro Ohara, Shinsuke Ishigaki, Jonathan K. Watts, Ken Yamada, Tsuneya Ikezu, Seiko Ikezu · 2026 · Molecular Neurodegeneration Advances
  48. Dual Roles of p53‐Related Protein Kinase in Cytoskeletal Remodeling and Translational Control
    Emiliano Molina, David Villarroel‐Campos, Manuel Muñoz, Álvaro Glavic, Christian Enrique González-Billault · 2026 · Journal of Neurochemistry
  49. BindingDB Entry 50020423: Small-molecule LRRK2 inhibitors for PD therapy: Current achievements and future perspectives.
    BindingDB · 2024 · UC San Diego